Nothing said here yet.
to join the conversation.
| Kim HyongChief Medical Officer | Sell | 32,479 | $269.6K | Tue, Oct 6 |
| KONOWIECKI JOSEPH SEVP, Corporate Affairs | Sell | 23,511 | $202.4K | Thu, Sep 17 |
| KAO JOHN EChief Executive Officer | Sell | 27,400 | $356.2K | Mon, Sep 14 |
| KAO JOHN EChief Executive Officer | Sell | 385,270 | $4.9M | Fri, Sep 11 |
| Maroney Dawn ChristinePresident | Sell | 122,707 | $1.6M | Fri, Sep 11 |
| KAO JOHN EChief Executive Officer | Sell | 172,600 | $2.2M | Thu, Sep 10 |
| Maroney Dawn ChristinePresident | Sell | 5,000 | $70.0K | Fri, Aug 14 |
Alignment Healthcare stock has been hit hard over the past few years, and with earnings now under a brighter spotlight, investors are asking whether the current valuation still lines up with the story they thought they owned.
Health insurance company Alignment Healthcare (NASDAQ:ALHC) beat Wall Street’s revenue expectations in Q3 2026, with sales up 36.7% year on year to $1.36 billion.
Alignment Healthcare (ALHC) just released its third quarter 2026 report, pairing revenue of about US$1.36b with a net loss of US$8.05m, along with updated guidance that lifts full year sales expectations.
Alignment Healthcare (NasdaqGS:ALHC) saw its California HMO plan Star Rating downgraded by the Centers for Medicare & Medicaid Services, removing eligibility for quality bonus payments.
Alignment Healthcare (NASDAQ:ALHC) reported third-quarter revenue growth of 37% as membership rose 31% from a year earlier, but the Medicare Advantage insurer lowered its full-year profitability outlook after elevated medical costs, provider appeals and…
Health insurance company Alignment Healthcare (NASDAQ:ALHC) will be reporting results this Thursday afternoon. Here’s what to look for.
Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.